News Flash:
|
We presented data from a chimeric mAb purification utilizing the AEX device as a post-clarification step promoting increased capacity and decreased fouling of the subsequent protein A column. Also, we will present data from an huIgG1 purification where AEX was employed as a polishing step post-CIEX. In both cases we will examine removal or reduction in residuals, including viral clearance data and resulting product quality attributes.
Jack Vicalvi, Manager, Purification & Bioconjugation, Downstream Process Development, Goodwin Biotechnology, Inc. |
Whether you are developing a mammalian cell culture-derived Monoclonal Antibody, Recombinant Protein, or Vaccine, you should consider Goodwin Biotechnology as your development and cGMP manufacturing partner, more...
|
With an extensive background in the purification of proteins from mammalian, plant and animal transgenic systems, Goodwin Biotechnology can quickly develop a purification process for subsequent cGMP manufacturing, more...
|
Goodwin Biotechnology offers a unique and unrivaled expertise in the research, process development, validation and cGMP manufacture of Antibody Drug Conjugates (ADCs), radioimmunoconjugates, and other protein more...
|
When developing a Biosimilar, companies will need to provide a significant amount of analytical, physical and clinical evidence to demonstrate that it is highly similar to the innovator. At Goodwin more...
|
BioProcess
International Meeting Boston, MA USA Booth # 201 October 26 - 29, 2015 |